Biocryst Pharmaceuticals Stock Earnings Reports

BioCryst reported a solid start to 2026 driven by ORLADEYO commercial momentum and pipeline progress. ORLADEYO net revenue was $148.3M in Q1, roughly in line with expectations, with monthly new patient prescriptions slightly ahead of 2025 averages and continued prescriber growth. The pediatric pellet launch has begun with prescriptions across all four strengths, but a manufacturing issue for the pediatric formulation was identified that will delay initial fulfillment; management expects to provide more detail later this quarter and does not expect the delay to change full-year 2026 revenue guidance. Clinical progress: the pivotal Phase 3 ALPHA-ORBIT trial for navenibart is enrolling ahead of plan and is expected to complete enrollment (~145 patients) by end of June, keeping the company on track for a U.S. regulatory filing by the end of 2027; the BCX17725 program (KLK5 inhibitor) for Netherton syndrome has started dosing in Part 4 and BioCryst expects proof-of-concept data by year-end from up to ~12 patients. Corporate/financial: the Astria acquisition closed (accounted as an asset acquisition, generating a $698M in-process R&D charge in Q1 GAAP results), BioCryst closed a $400M senior credit facility, and finalized a European license for navenibart with Neopharmed Gentili ( $70M upfront, up to $275M in milestones, tiered royalties ~18–30%). Management highlights strong non-GAAP performance (Q1 non-GAAP operating profit $54M, non-GAAP revenue growth ~17% YoY) and pro forma liquidity of ~$331M as of March 31, 2026. Guidance: ORLADEYO full-year 2026 revenue unchanged at $625–645M; full-year non-GAAP OpEx $450–470M. The company also discontinued avoralstat in DME and says it will continue a disciplined, rare-disease-focused R&D strategy.